Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab

Retina

Volumn 33, Issue 9, 2013, Pages 1843-1849

  Wolf, Armin ^a   Rüping, Johann ^a   Neubauer, Aljoscha S ^a   Mayer, Wolfgang ^a   Ulbig, Michael ^a   Haritoglou, Christos ^a   Holz, Frank G ^b   Eter, Nicole ^c   Kampik, Anselm ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

AMD; pigment epithelium detachment; ranibizumab

Indexed keywords

RANIBIZUMAB;

ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84885019016     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318287d9be     Document Type: Article

References (40)

1. Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond) 2009;23: 2163-2168.
2. Pauleikhoff D, Loffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002;240:533-538. (Pubitemid 36097080)
3. Wasmuth S. [Pathogenetic concepts for pigment epithelial detachment in exudative AMD]. Ophthalmologe 2010;107: 1109-1114.
4. Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 1985;69:397-403. (Pubitemid 15059051)
5. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-671.
6. Holz FG, Korobelnik JF, Lanzetta P, et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010;51:405-412.
7. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
8. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
9. Freeman WR, Kozak I, Yuson RM, et al. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Retina 2011;31:1812-1818.
10. Yeh B, Ferrucci S. Retinal pigment epithelium tears after bevacizumab injection. Optometry 2011;82:152-157.
11. Ach T, Hoeh AE, Ruppenstein M, et al. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina 2010;30:1420-1425.
12. Ruppenstein M, Ach T, Hoh A, Dithmar S. [Effect of intravitreal bevacizumab on pigment epithelial detachment in occult choroidal neovascularization]. Ophthalmologe 2010;107:827-830.
13. Leitritz M, Gelisken F, Inhoffen W, et al Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography study. Eye (Lond) 2008;22:1504-1507.
14. Kook D, Wolf A, Neubauer AS, et al. [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress]. Ophthalmologe 2008;105: 158-164.
15. Kaiser RS, Gupta OP, Regillo CD, et al. Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response. Ophthalmic Surg Lasers Imaging 2012;43:13-19.
16. Arora S, McKibbin M. One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye (Lond) 2011;25:1034-1038.
17. Loukianou E, Kisma N, Hamilton R. Complete resolution of a giant pigment epithelial detachment secondary to exudative age-related macular degeneration after a single intravitreal ranibizumab (lucentis) injection: results documented by optical coherence tomography. Case Rep Ophthalmol 2010;1:110-113.
18. Ritter M, Bolz M, Sacu S, et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye (Lond) 2010;24:962-968.
19. Joeres S, Tsong JW, Updike PG, et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2007;48:4300-4307. (Pubitemid 351261062)
20. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1242-1257.
21. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No.2. Arch Ophthalmol 2003; 121:1253-1268.
22. Haefeli M, Elfering A, McIntosh E, et al. A cost-benefit analysis using contingent valuation techniques: a feasibility study in spinal surgery. Value Health 2008;11:575-588. (Pubitemid 352032802)
23. Boos DD. Introduction to the Bootstrap World. Statist Sci 2003;18:168-174. (Pubitemid 37545089)
24. Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008; 92:1642-1647.
25. Cukras C, Agron E, Klein ML, et al. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No.28. Ophthalmology 2010;117:489-499.
26. Shima C, Gomi F, Sawa M, et al. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:899-906.
27. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.e5.
28. Bolz M, Michels S, Geitzenauer W, et al. Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 2007;91:785-789. (Pubitemid 46846651)
29. Ladas ID, Kotsolis AI, Papakostas TD, et al. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina 2007;27:891-896. (Pubitemid 47479383)
30. Frimpong-Boateng A, Varde MA, Rufer F, et al. [Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD]. Ophthalmologe 2008;105:661-668.
31. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:3115-3120.
32. Arias L. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clin Ophthalmol 2010;4:369-374.
33. el Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248:779-784.
34. Bird AC. Doyne Lecture. Pathogenesis of retinal pigment epithelial detachment in the elderly; the relevance of Bruch's membrane change. Eye (Lond) 1991;5:1-12.
35. Gass JD. Pathogenesis of tears of the retinal pigment epithelium. Br J Ophthalmol 1984;68:513-519. (Pubitemid 15135455)
36. Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol 2009;147:644-652.
37. Gupta B, Jyothi S, Sivaprasad S. Current treatment options for retinal angiomatous proliferans (RAP). Br J Ophthalmol 2010; 94:672-677.
38. Chin EK, Sedeek RW, Li Y, et al. Reproducibility of macular thickness measurement among five OCT instruments: effects of image resolution, image registration, and eye tracking. Ophthalmic Surg Lasers Imaging 2012;43:97-108.
39. Smretschnig E, Krebs I, Moussa S, et al. Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment. Graefes Arch Clin Exp Ophthalmol 2010;248:1693-1698.
40. Reznicek L. 1.4 Mhz Ultra High-speed Ultra Wide-field Swept Source OCT. Arvo Abstract, 1754/A234 2011.